Evidence map›Paper›PMID 39018024›Full record

ArticleThe American journal of gastroenterology2025

The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints.

Elliot B Tapper, David Goldberg, Neehar D Parikh, Norah A Terrault, Nicole Welch, Suzanne Sharpton, Bilal Hameed, Mandana Khalili, Andrew Stolz, Elizabeth C Verna and 13 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in The American journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05740358 (Liver Cirrhosis Network Cohort Study), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05740358 active not recruitingnot on this map

Liver Cirrhosis Network Cohort Study

TypeobservationalSponsorNorthwestern UniversityRan2022 to 2030Enrolled1,222ConditionsCirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Disease Modulating Agents in Cirrhosis.Clinics in liver disease · 2026
    Review
  11. Article
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Elliot B TapperDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
David GoldbergDivision of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.ORCID 0000-0002-1465-0691
Neehar D ParikhDivision of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0002-5874-9933
Norah A TerraultDivision of Gastrointestinal and Liver Diseases, Keck Medicine of University of Southern California, Los Angeles, California, USA.
Nicole WelchDepartment of Gastroenterology, Hepatology & Nutrition, Cleveland Clinic, Cleveland, Ohio, USA.ORCID 0000-0002-4655-5146
Suzanne SharptonNAFLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, California, USA.
Bilal HameedDivision of Gastroenterology and Hepatology, University of California-San Francisco, San Francisco, California, USA.
Mandana KhaliliDivision of Gastroenterology and Hepatology, University of California-San Francisco, San Francisco, California, USA.ORCID 0000-0001-9178-9139
Andrew StolzDivision of Gastrointestinal and Liver Diseases, Keck Medicine of University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-1443-9351
Elizabeth C VernaDivision of Digestive and Liver Diseases, Columbia University, New York, New York, USA.
Robert S BrownDivision of Gastroenterology & Hepatology, Weill Cornell Medicine New York, New York, USA.
Arun J SanyalDivision of Gastroenterology and Hepatology, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA.ORCID 0000-0001-8682-5748
Lisa VanWagnerDivision of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-6264-2573
Daniela P LadnerDivision of Transplantation, Department of Surgery, Northwestern University, Chicago, Illinois, USA.ORCID 0000-0001-5526-8272
Cynthia A MoylanDivision of Gastroenterology and Hepatology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0001-8454-7086
Anna Mae DiehlDivision of Gastroenterology and Hepatology, Duke University School of Medicine, Durham, North Carolina, USA.
Patricia D JonesDivision of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.ORCID 0000-0003-4189-6731
Rohit LoombaNAFLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, California, USA.ORCID 0000-0002-4845-9991
Srinivasan DasarathyDepartment of Gastroenterology, Hepatology & Nutrition, Cleveland Clinic, Cleveland, Ohio, USA.
Douglas A SimonettoDivision of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota, USA .ORCID 0000-0003-4095-8144
Vijay H ShahDivision of Gastroenterology and Hepatology, Mayo Clinic Rochester, Rochester, Minnesota, USA .ORCID 0000-0001-7620-573
Jasmohan S BajajDivision of Gastroenterology and Hepatology, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA.ORCID 0000-0003-4928-3681
LCN Study Group

Funding

Project Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI LAURA E. NAGY · 2016 to 2026
$19.6M
Liver Cirrhosis Network: Scientific and Data Coordination CenterU24DK130164 · NIDDK · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Lauren Balmert Bonner, Daniela P Ladner · 2021 to 2026
$12.8M
Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapyU01DK130180 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2021 to 2026
$3.9M
Liver Cirrhosis Network: Longitudinal and Clinical Trial StudiesU01DK130168 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bilal Hameed, Mandana Khalili · 2021 to 2026
$3.7M
Statin Therapy for patients with compensated CirrhosisU01DK130113 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Neehar Dilip Parikh, Elliot Tapper · 2021 to 2026
$3.4M
Strategies and Therapies for Outcomes Prevention in Cirrhosis: The STOP-C Liver Cirrhosis NetworkU01DK130221 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROBERT S BROWN, Elizabeth Clarice Verna · 2021 to 2026
$3.0M
Evaluating the impact of genetic ancestry and HIV on cirrhosis progression and response to statin therapy among a diverse multi-ethnic cohort of patients with cirrhosisU01DK130185 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI David Seth Goldberg · 2021 to 2026
$2.4M
San Diego Cirrhosis Clinical Research NetworkU01DK130190 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ROHIT LOOMBA · 2021 to 2026
$2.3M
USC Cirrhosis Clinical CenterU01DK130197 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Norah A. Terrault · 2021 to 2026
$2.1M
Prediction and Prevention of Hepatic Decompensation in Patients with CirrhosisU01DK130177 · NIDDK · DUKE UNIVERSITY · PI MATTHEW R. KAPPUS, Cynthia A Moylan · 2021 to 2026
$2.0M
Liver Cirrhosis Network: Clinical Research CentersU01DK130134 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI Jasmohan S Bajaj, ARUN J SANYAL · 2021 to 2026
$2.0M
Liver Cirrhosis Network: Clinical Research Center - Mayo ClinicU01DK130181 · NIDDK · MAYO CLINIC ROCHESTER · PI VIJAY H. SHAH, Douglas A. Simonetto · 2021 to 2026
$1.9M
American Diabetes Association U01DK130177NIAAA NIH HHS K08 AA028794NIAAA NIH HHS P50 AA024333NIDDK NIH HHS U01 DK130113NIDDK NIH HHS U01DK130113NIDDK NIH HHS U01 DK130134NIDDK NIH HHS U01DK130134NIDDK NIH HHS U01 DK130168NIDDK NIH HHS U01DK130168NIDDK NIH HHS U01 DK130177NIDDK NIH HHS U01 DK130180NIDDK NIH HHS U01DK130180NIDDK NIH HHS U01 DK130181NIDDK NIH HHS U01DK130181NIDDK NIH HHS U01 DK130185NIDDK NIH HHS U01DK130185NIDDK NIH HHS U01 DK130190NIDDK NIH HHS U01DK130190NIDDK NIH HHS U01 DK130197NIDDK NIH HHS U01DK130197NIDDK NIH HHS U01 DK130221NIDDK NIH HHS U01DK130221NIDDK NIH HHS U24 DK130164NIDDK NIH HHS U24DK130164
6 · The paper itself

Abstract

introductionOne of the primary goals of the Liver Cirrhosis Network (LCN) is to develop a cohort study to better understand and predict the risk of hepatic decompensation and other clinical and patient-reported outcomes among patients with Child A cirrhosis.

methodsThe LCN consists of a Scientific Data Coordinating Center and 10 clinical centers whose investigators populate multiple committees. The LCN Definitions and Measurements Committee developed preliminary definitions of cirrhosis and its complications by literature review, expert opinion, and reviewing definition documents developed by other organizations. The Cohort Committee developed the study protocol with the input of the steering committee.

resultsThe LCN developed a prospective cohort study to describe and predict the rates of incident clinical events pertaining to first decompensation and patient-reported outcomes. The LCN developed a pragmatic definition of compensated cirrhosis incorporating clinical, laboratory, imaging, and histological criteria. Definitions of incident and recompensated ascites, overt hepatic encephalopathy, variceal hemorrhage, bleeding because of portal gastropathy, and hepatocellular carcinoma were also codified. DISCUSSION: The LCN Cohort Study design will inform the natural history of cirrhosis in contemporary patients with compensated cirrhosis. The LCN Definitions and Measures Committee developed criteria for the definition of cirrhosis to standardize entry into this multicenter cohort study and standardized criteria for liver-related outcome measures. This effort has produced definitions intended to be both sensitive and specific as well as easily operationalized by study staff such that outcomes critical to the LCN cohort are identified and reported in an accurate and generalizable fashion. REGISTRATION: NCT05740358.

Indexed as

Liver CirrhosisAdolescentAdultAgedAged, 80 and overAscitesCarcinoma, HepatocellularCohort StudiesEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHepatic EncephalopathyHumansLiver NeoplasmsMaleMiddle Aged

Identifiers

PMID39018024
PMCPMC11739427

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.